FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4296131173> ?p ?o ?g. }

• W4296131173 endingPage "A015" @default.
• W4296131173 startingPage "A015" @default.
• W4296131173 abstract "Abstract Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children. Although FOXO1 fusions portend a dismal prognosis for patients with both localized (5-year survival 65%) and metastatic (19%) disease, current therapy is largely agnostic to fusion status. The allosteric mTORC1 inhibitor temsirolimus delays disease progression in relapsed RMS but does not improve survival. We hypothesized that this incomplete response is due to inadequate suppression of critical downstream effectors of the mTORC1 complex. Recently described bi-steric mTORC1-selective inhibitors combine allosteric and catalytic modes of kinase inhibition, and have shown promise in diverse preclinical cancer models with early evidence of clinical activity. We therefore set out to compare the activity of the bi-steric mTORC1-selective inhibitor RMC-6272 to the allosteric mTOR inhibitor rapamycin in cell line and xenograft models of fusion positive RMS. Methods: We compared the in vitro anti-proliferative activity of RMC-6272 and rapamycin in FOXO1 fusion positive RMS cell lines at 72 and 144 hours. We assessed the ability of these inhibitors to suppress mTORC1 outputs, using immunoblot to quantify phosphorylation of p70S6K, RPS6, and 4EBP1, and m7-GTP pulldowns to assess repression of cap-dependent translation. In vivo studies were conducted in patient-derived xenograft (PDX) models subcutaneously implanted in NSG mice. We tested preclinical anti-tumor activity of RMC-6272 at two doses and used immunoblots and m7-GTP assays in tumors harvested from treated mice to assess target engagement. Results: We observed superior anti-proliferative effects of RMC-6272 when compared to rapamycin in vitro, with the latter having only modest effect. Biochemically, treatment of RMS cell lines with either RMC-6272 or rapamycin diminished phosphorylation of p70S6K and RPS6. However, RMC-6272 blocked 4EBP1 phosphorylation and cap-dependent translation much more potently than rapamycin. Based on these findings, we conducted in vivo studies using weekly intraperitoneal injections of RMC-6272 in PDX-harboring mice. Both doses were associated with tumor regressions in two fusion positive RMS PDX models: 2 CR and 1 PR at 8 mg/kg, and 3 CR, 1 PR, 1 SD, and 2 PD at 6 mg/kg. NSG mice treated at 8 mg/kg demonstrated more weight loss than those at 6 mg/kg, suggesting strain-specific determinants of tolerability. We confirmed in vivo suppression of p70S6K phosphorylation and cap-dependent translation in tumors. Conclusions: The mTORC1 inhibitor RMC-6272 exhibits greater anti-tumor activity than the allosteric inhibitor rapamycin in vitro, and is capable of inducing complete remissions as monotherapy in FOXO1 fusion positive RMS PDX. Increased anti-tumor activity was associated with suppression of cap-dependent translation as assessed by m7-GTP assays, nominating dephosphorylation of 4EBP1 as a potential response biomarker. Preclinical studies are ongoing to assess mechanism-informed combination therapeutic strategies incorporating this highly active agent in FOXO1 fusion positive RMS. Citation Format: Jacqueline Morales, Kristen Kwong, W. Clay Gustafson, Amit J. Sabnis. Biochemical and preclinical anti-tumor activity of a bi-steric mTORC1-selective inhibitor in fusion positive rhabdomyosarcoma [abstract]. In: Proceedings of the AACR Special Conference: Sarcomas; 2022 May 9-12; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2022;28(18_Suppl):Abstract nr A015." @default.
• W4296131173 created "2022-09-17" @default.
• W4296131173 creator A5024176070 @default.
• W4296131173 creator A5045844134 @default.
• W4296131173 creator A5062181362 @default.
• W4296131173 creator A5082896068 @default.
• W4296131173 date "2022-09-15" @default.
• W4296131173 modified "2023-09-27" @default.
• W4296131173 title "Abstract A015: Biochemical and preclinical anti-tumor activity of a bi-steric mTORC1-selective inhibitor in fusion positive rhabdomyosarcoma" @default.
• W4296131173 doi "https://doi.org/10.1158/1557-3265.sarcomas22-a015" @default.
• W4296131173 hasPublicationYear "2022" @default.
• W4296131173 type Work @default.
• W4296131173 citedByCount "0" @default.
• W4296131173 crossrefType "journal-article" @default.
• W4296131173 hasAuthorship W4296131173A5024176070 @default.
• W4296131173 hasAuthorship W4296131173A5045844134 @default.
• W4296131173 hasAuthorship W4296131173A5062181362 @default.
• W4296131173 hasAuthorship W4296131173A5082896068 @default.
• W4296131173 hasConcept C126322002 @default.
• W4296131173 hasConcept C142724271 @default.
• W4296131173 hasConcept C150903083 @default.
• W4296131173 hasConcept C166342909 @default.
• W4296131173 hasConcept C170493617 @default.
• W4296131173 hasConcept C207001950 @default.
• W4296131173 hasConcept C2778256501 @default.
• W4296131173 hasConcept C2780844630 @default.
• W4296131173 hasConcept C502942594 @default.
• W4296131173 hasConcept C62478195 @default.
• W4296131173 hasConcept C71924100 @default.
• W4296131173 hasConcept C86554907 @default.
• W4296131173 hasConcept C86803240 @default.
• W4296131173 hasConcept C95444343 @default.
• W4296131173 hasConcept C98274493 @default.
• W4296131173 hasConcept C98490376 @default.
• W4296131173 hasConceptScore W4296131173C126322002 @default.
• W4296131173 hasConceptScore W4296131173C142724271 @default.
• W4296131173 hasConceptScore W4296131173C150903083 @default.
• W4296131173 hasConceptScore W4296131173C166342909 @default.
• W4296131173 hasConceptScore W4296131173C170493617 @default.
• W4296131173 hasConceptScore W4296131173C207001950 @default.
• W4296131173 hasConceptScore W4296131173C2778256501 @default.
• W4296131173 hasConceptScore W4296131173C2780844630 @default.
• W4296131173 hasConceptScore W4296131173C502942594 @default.
• W4296131173 hasConceptScore W4296131173C62478195 @default.
• W4296131173 hasConceptScore W4296131173C71924100 @default.
• W4296131173 hasConceptScore W4296131173C86554907 @default.
• W4296131173 hasConceptScore W4296131173C86803240 @default.
• W4296131173 hasConceptScore W4296131173C95444343 @default.
• W4296131173 hasConceptScore W4296131173C98274493 @default.
• W4296131173 hasConceptScore W4296131173C98490376 @default.
• W4296131173 hasIssue "18_Supplement" @default.
• W4296131173 hasLocation W42961311731 @default.
• W4296131173 hasOpenAccess W4296131173 @default.
• W4296131173 hasPrimaryLocation W42961311731 @default.
• W4296131173 hasRelatedWork W1593973180 @default.
• W4296131173 hasRelatedWork W2026140947 @default.
• W4296131173 hasRelatedWork W2101083009 @default.
• W4296131173 hasRelatedWork W2115508086 @default.
• W4296131173 hasRelatedWork W2330924021 @default.
• W4296131173 hasRelatedWork W2406111920 @default.
• W4296131173 hasRelatedWork W2617848394 @default.
• W4296131173 hasRelatedWork W2958505263 @default.
• W4296131173 hasRelatedWork W3001607621 @default.
• W4296131173 hasRelatedWork W3013476818 @default.
• W4296131173 hasVolume "28" @default.
• W4296131173 isParatext "false" @default.
• W4296131173 isRetracted "false" @default.
• W4296131173 workType "article" @default.